To evaluate the effects of the treatment of HMA plus VEN on circulating immune cell repertoire, we first analyzed CD4+ and CD8+ T cell subsets in the PB of AML patients during treatment, compared to PB examined before treatment (baseline). This evidence concerns the gene CD4 and acute myeloid leukemia.